As the field of thyroid cancer research continues to advance, understanding the role of DPP-IV and SGLT2 inhibitors in potential PTC management may offer new avenues for improving patient outcomes and expanding the therapeutic armamentarium for this prevalent malignancy. The gene discussed is SLC5A2; the disease is thyroid gland carcinoma.